Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.retram.2020.06.003 http://scihub22266oqcxt.onion/10.1016/j.retram.2020.06.003 32620465!7321051!32620465     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Curr+Res+Transl+Med 2020 ; 68 (3): 111-118 Nephropedia Template TP {{tp|p=32620465|t=2020. CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges |pdf=|usr=}}{{32620465}} gab.com Text CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges JO: Curr Res Transl Med http://www.kidney.de/pget.php?&tw=1&pmid=32620465 #FOAvip The pandemic of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly across the world. Currently, the COVID-19 pandemic is affecting the continuity of essential routine healthcare services and procedures, including chimeric antigen receptor T-cell (CAR-T) therapy, a life-saving option for patients with relapsed/refractory (R/R) hematologic malignancies. Due to the rapid disease progression of hematological malignancies, there is an urgent need to manufacture and utilize CAR T-cells. However, CAR-T treatment has become extraordinarily challenging during this COVID-19 pandemic. Thus, many medical and technical factors must now be taken into consideration before, during, and after CAR-T therapy. The purpose of this review is to provide brief suggestions for rational decision-making strategies in evaluating and selecting CAR T-cell treatment and appropriate CAR T-cell products, and protective strategies for medical staff and patients to prevent infection in the midst of the current COVID-19 pandemic. Twit Text FOAVip CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges ????Curr Res Transl Med http://www.kidney.de/pget.php?&tw=1&pmid=32620465 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32620465 #FOAvip English Wikipedia <ref>{{Cite pmid|32620465}}</ref> CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges #MMPMID32620465 Hu Y; Tan Su Yin E; Yang Y; Wu H; Wei G; Su J; Cui Q; Jin A; Yang L; Fu S; Zhou J; Qiu L; Zhang X; Liang A; Jing H; Li Y; Blaise D; Mohty M; Nagler A; Huang H Curr Res Transl Med 2020[Aug]; 68 (3): 111-118 PMID32620465show ga The pandemic of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly across the world. Currently, the COVID-19 pandemic is affecting the continuity of essential routine healthcare services and procedures, including chimeric antigen receptor T-cell (CAR-T) therapy, a life-saving option for patients with relapsed/refractory (R/R) hematologic malignancies. Due to the rapid disease progression of hematological malignancies, there is an urgent need to manufacture and utilize CAR T-cells. However, CAR-T treatment has become extraordinarily challenging during this COVID-19 pandemic. Thus, many medical and technical factors must now be taken into consideration before, during, and after CAR-T therapy. The purpose of this review is to provide brief suggestions for rational decision-making strategies in evaluating and selecting CAR T-cell treatment and appropriate CAR T-cell products, and protective strategies for medical staff and patients to prevent infection in the midst of the current COVID-19 pandemic. |*Immunotherapy, Adoptive/methods/trends[MESH] |Betacoronavirus/physiology[MESH] |COVID-19[MESH] |Coronavirus Infections/epidemiology/*prevention & control[MESH] |Delivery of Health Care/methods/*organization & administration/standards/trends[MESH] |Hematologic Neoplasms/epidemiology/*therapy[MESH] |Humans[MESH] |Infection Control/methods/*organization & administration/standards/trends[MESH] |Pandemics/*prevention & control[MESH] |Pneumonia, Viral/epidemiology/*prevention & control[MESH] |Preventive Health Services/methods/organization & administration/standards/trends[MESH] |Receptors, Antigen, T-Cell/*immunology[MESH]CAR T-cell treatment during the COVID-19 pandemic: Management strategi(epmc).pdf DeepDyve Pubget Overpricing